Is GMRS or LFMD more profitable?

LifeMD has a net margin of 0.10% compared to GMR Solutions' net margin of 0.00%. GMR Solutions' return on equity of 0.00% beat LifeMD's return on equity. Company Net Margins Return on Equity Return on Assets GMR Solutions N/A N/A N/A LifeMD 0.10% -168.23% -31.27%

Does the media prefer GMRS or LFMD?

In the previous week, LifeMD had 14 more articles in the media than GMR Solutions. MarketBeat recorded 17 mentions for LifeMD and 3 mentions for GMR Solutions. LifeMD's average media sentiment score of 0.57 beat GMR Solutions' score of 0.04 indicating that LifeMD is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GMR Solutions 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral LifeMD 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Is LFMD or FLGT more profitable?

LifeMD has a net margin of 0.10% compared to Fulgent Genetics' net margin of -26.05%. Fulgent Genetics' return on equity of -4.93% beat LifeMD's return on equity. Company Net Margins Return on Equity Return on Assets LifeMD 0.10% -168.23% -31.27% Fulgent Genetics -26.05% -4.93% -4.50%

Does the media favor SRTA or LFMD?

In the previous week, LifeMD had 13 more articles in the media than Strata Critical Medical. MarketBeat recorded 17 mentions for LifeMD and 4 mentions for Strata Critical Medical. Strata Critical Medical's average media sentiment score of 0.59 beat LifeMD's score of 0.57 indicating that Strata Critical Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Strata Critical Medical 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive LifeMD 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

LifeMD (LFMD) Competitors

$3.40 +0.13 (+3.98%)

Closing price 04:00 PM Eastern

Extended Trading

$3.44 +0.04 (+1.03%)

As of 07:43 PM Eastern

Compare

LFMD vs. GMRS, FLGT, TOI, SRTA, and CCRN

Should you buy LifeMD stock or one of its competitors? LifeMD's main competitors and comparable companies include GMR Solutions (GMRS), Fulgent Genetics (FLGT), Oncology Institute (TOI), Strata Critical Medical (SRTA), and Cross Country Healthcare (CCRN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does LifeMD compare to GMR Solutions?

GMR Solutions (NYSE:GMRS) and LifeMD (NASDAQ:LFMD) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, valuation, risk and analyst recommendations.

35.5% of LifeMD shares are held by institutional investors. 17.2% of LifeMD shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

GMR Solutions presently has a consensus price target of $18.67, indicating a potential upside of 30.17%. LifeMD has a consensus price target of $7.57, indicating a potential upside of 122.69%. Given LifeMD's higher probable upside, analysts plainly believe LifeMD is more favorable than GMR Solutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GMR Solutions	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.70
LifeMD	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

LifeMD has higher revenue and earnings than GMR Solutions. LifeMD is trading at a lower price-to-earnings ratio than GMR Solutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GMR Solutions	N/A	N/A	N/A	$0.28	51.21
LifeMD	$194.05M	0.84	$14.35M	-$0.05	N/A

In the previous week, LifeMD had 14 more articles in the media than GMR Solutions. MarketBeat recorded 17 mentions for LifeMD and 3 mentions for GMR Solutions. LifeMD's average media sentiment score of 0.57 beat GMR Solutions' score of 0.04 indicating that LifeMD is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GMR Solutions	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
LifeMD	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

LifeMD has a net margin of 0.10% compared to GMR Solutions' net margin of 0.00%. GMR Solutions' return on equity of 0.00% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GMR Solutions	N/A	N/A	N/A
LifeMD	0.10%	-168.23%	-31.27%

Summary

LifeMD beats GMR Solutions on 8 of the 13 factors compared between the two stocks.

How does LifeMD compare to Fulgent Genetics?

LifeMD (NASDAQ:LFMD) and Fulgent Genetics (NASDAQ:FLGT) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

LifeMD has higher earnings, but lower revenue than Fulgent Genetics. LifeMD is trading at a lower price-to-earnings ratio than Fulgent Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LifeMD	$194.05M	0.84	$14.35M	-$0.05	N/A
Fulgent Genetics	$322.67M	1.68	-$60.51M	-$2.82	N/A

In the previous week, LifeMD had 17 more articles in the media than Fulgent Genetics. MarketBeat recorded 17 mentions for LifeMD and 0 mentions for Fulgent Genetics. LifeMD's average media sentiment score of 0.57 beat Fulgent Genetics' score of 0.00 indicating that LifeMD is being referred to more favorably in the media.

Company	Overall Sentiment
LifeMD	Positive
Fulgent Genetics	Neutral

LifeMD has a net margin of 0.10% compared to Fulgent Genetics' net margin of -26.05%. Fulgent Genetics' return on equity of -4.93% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LifeMD	0.10%	-168.23%	-31.27%
Fulgent Genetics	-26.05%	-4.93%	-4.50%

LifeMD currently has a consensus price target of $7.57, indicating a potential upside of 122.69%. Fulgent Genetics has a consensus price target of $27.50, indicating a potential upside of 39.31%. Given LifeMD's stronger consensus rating and higher probable upside, research analysts clearly believe LifeMD is more favorable than Fulgent Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LifeMD	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

35.5% of LifeMD shares are owned by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are owned by institutional investors. 17.2% of LifeMD shares are owned by company insiders. Comparatively, 36.2% of Fulgent Genetics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

LifeMD has a beta of 2.02, indicating that its stock price is 102% more volatile than the broader market. Comparatively, Fulgent Genetics has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market.

Summary

LifeMD beats Fulgent Genetics on 9 of the 16 factors compared between the two stocks.

How does LifeMD compare to Oncology Institute?

LifeMD (NASDAQ:LFMD) and Oncology Institute (NASDAQ:TOI) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.

In the previous week, LifeMD had 17 more articles in the media than Oncology Institute. MarketBeat recorded 17 mentions for LifeMD and 0 mentions for Oncology Institute. LifeMD's average media sentiment score of 0.57 beat Oncology Institute's score of 0.00 indicating that LifeMD is being referred to more favorably in the media.

Company	Overall Sentiment
LifeMD	Positive
Oncology Institute	Neutral

LifeMD has higher earnings, but lower revenue than Oncology Institute. LifeMD is trading at a lower price-to-earnings ratio than Oncology Institute, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LifeMD	$194.05M	0.84	$14.35M	-$0.05	N/A
Oncology Institute	$545.76M	0.94	-$60.61M	-$0.37	N/A

LifeMD has a net margin of 0.10% compared to Oncology Institute's net margin of -7.42%. Oncology Institute's return on equity of 0.00% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LifeMD	0.10%	-168.23%	-31.27%
Oncology Institute	-7.42%	N/A	-24.68%

LifeMD has a beta of 2.02, suggesting that its share price is 102% more volatile than the broader market. Comparatively, Oncology Institute has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market.

LifeMD presently has a consensus target price of $7.57, suggesting a potential upside of 122.69%. Oncology Institute has a consensus target price of $8.50, suggesting a potential upside of 63.90%. Given LifeMD's stronger consensus rating and higher possible upside, research analysts plainly believe LifeMD is more favorable than Oncology Institute.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LifeMD	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Oncology Institute	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

35.5% of LifeMD shares are held by institutional investors. Comparatively, 36.9% of Oncology Institute shares are held by institutional investors. 17.2% of LifeMD shares are held by insiders. Comparatively, 4.4% of Oncology Institute shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

LifeMD beats Oncology Institute on 10 of the 16 factors compared between the two stocks.

How does LifeMD compare to Strata Critical Medical?

Strata Critical Medical (NASDAQ:SRTA) and LifeMD (NASDAQ:LFMD) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.

47.4% of Strata Critical Medical shares are held by institutional investors. Comparatively, 35.5% of LifeMD shares are held by institutional investors. 15.5% of Strata Critical Medical shares are held by company insiders. Comparatively, 17.2% of LifeMD shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Strata Critical Medical has higher revenue and earnings than LifeMD. Strata Critical Medical is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Strata Critical Medical	$197.14M	2.64	$41.35M	-$0.04	N/A
LifeMD	$194.05M	0.84	$14.35M	-$0.05	N/A

In the previous week, LifeMD had 13 more articles in the media than Strata Critical Medical. MarketBeat recorded 17 mentions for LifeMD and 4 mentions for Strata Critical Medical. Strata Critical Medical's average media sentiment score of 0.59 beat LifeMD's score of 0.57 indicating that Strata Critical Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Strata Critical Medical	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
LifeMD	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Strata Critical Medical has a net margin of 15.71% compared to LifeMD's net margin of 0.10%. Strata Critical Medical's return on equity of -2.97% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Strata Critical Medical	15.71%	-2.97%	-2.54%
LifeMD	0.10%	-168.23%	-31.27%

Strata Critical Medical presently has a consensus target price of $8.00, indicating a potential upside of 35.82%. LifeMD has a consensus target price of $7.57, indicating a potential upside of 122.69%. Given LifeMD's higher possible upside, analysts clearly believe LifeMD is more favorable than Strata Critical Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Strata Critical Medical	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.75
LifeMD	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Strata Critical Medical has a beta of 2.25, meaning that its stock price is 125% more volatile than the broader market. Comparatively, LifeMD has a beta of 2.02, meaning that its stock price is 102% more volatile than the broader market.

Summary

Strata Critical Medical beats LifeMD on 12 of the 17 factors compared between the two stocks.

How does LifeMD compare to Cross Country Healthcare?

LifeMD (NASDAQ:LFMD) and Cross Country Healthcare (NASDAQ:CCRN) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

In the previous week, LifeMD had 17 more articles in the media than Cross Country Healthcare. MarketBeat recorded 17 mentions for LifeMD and 0 mentions for Cross Country Healthcare. LifeMD's average media sentiment score of 0.57 beat Cross Country Healthcare's score of 0.00 indicating that LifeMD is being referred to more favorably in the media.

Company	Overall Sentiment
LifeMD	Positive
Cross Country Healthcare	Neutral

35.5% of LifeMD shares are held by institutional investors. Comparatively, 96.0% of Cross Country Healthcare shares are held by institutional investors. 17.2% of LifeMD shares are held by insiders. Comparatively, 6.3% of Cross Country Healthcare shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

LifeMD has a net margin of 0.10% compared to Cross Country Healthcare's net margin of -9.84%. Cross Country Healthcare's return on equity of -0.74% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LifeMD	0.10%	-168.23%	-31.27%
Cross Country Healthcare	-9.84%	-0.74%	-0.54%

LifeMD has a beta of 2.02, meaning that its share price is 102% more volatile than the broader market. Comparatively, Cross Country Healthcare has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market.

LifeMD currently has a consensus price target of $7.57, indicating a potential upside of 122.69%. Cross Country Healthcare has a consensus price target of $12.05, indicating a potential downside of 9.06%. Given LifeMD's stronger consensus rating and higher probable upside, analysts plainly believe LifeMD is more favorable than Cross Country Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LifeMD	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Cross Country Healthcare	1 Sell rating(s)	9 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.90

LifeMD has higher earnings, but lower revenue than Cross Country Healthcare. LifeMD is trading at a lower price-to-earnings ratio than Cross Country Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LifeMD	$194.05M	0.84	$14.35M	-$0.05	N/A
Cross Country Healthcare	$1.00B	0.43	-$94.85M	-$3.05	N/A

Summary

LifeMD beats Cross Country Healthcare on 11 of the 16 factors compared between the two stocks.

Get LifeMD News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LFMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LFMD vs. The Competition

Export

Metric	LifeMD	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$157.62M	$9.78B	$7.17B	$12.86B
Dividend Yield	N/A	2.54%	2.55%	10.54%
P/E Ratio	-67.99	29.94	209.34	20.93
Price / Sales	0.84	4.96	618.74	95.86
Price / Cash	N/A	126.93	78.23	52.73
Price / Book	20.00	3.96	13.21	6.25
Net Income	$14.35M	$311.06M	$3.47B	$348.04M
7 Day Performance	3.34%	0.50%	2.41%	0.35%
1 Month Performance	-18.07%	-0.43%	4.29%	1.99%
1 Year Performance	-44.35%	17.61%	29.18%	21.11%

LifeMD Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LFMD LifeMD	3.1184 of 5 stars	$3.40 +4.0%	$7.57 +122.7%	-49.8%	$157.62M	$194.05M	N/A	230	Analyst Upgrade Analyst Revision
GMRS GMR Solutions	4.7036 of 5 stars	$12.64 +0.5%	$19.22 +52.1%	N/A	$679.47M	N/A	45.14	N/A	Earnings Report Analyst Forecast
FLGT Fulgent Genetics	2.6772 of 5 stars	$19.06 -0.4%	$27.50 +44.3%	-13.7%	$526.64M	$322.67M	N/A	1,315
TOI Oncology Institute	2.4323 of 5 stars	$5.19 +1.1%	$8.50 +63.9%	+28.4%	$512.58M	$545.76M	N/A	660	Gap Down
SRTA Strata Critical Medical	2.3849 of 5 stars	$5.94 +2.6%	$8.00 +34.7%	N/A	$500.99M	$197.14M	N/A	130

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LFMD) was last updated on 8/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LifeMD (LFMD) Competitors

LFMD vs. GMRS, FLGT, TOI, SRTA, and CCRN

How does LifeMD compare to GMR Solutions?

Summary

How does LifeMD compare to Fulgent Genetics?

Summary

How does LifeMD compare to Oncology Institute?

Summary

How does LifeMD compare to Strata Critical Medical?

Summary

How does LifeMD compare to Cross Country Healthcare?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFMD vs. The Competition

LifeMD Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

LifeMD (LFMD) Competitors

LFMD vs. GMRS, FLGT, TOI, SRTA, and CCRN

How does LifeMD compare to GMR Solutions?

Do insiders and institutionals believe in GMRS or LFMD?

Do analysts rate GMRS or LFMD?

Which has better earnings & valuation, GMRS or LFMD?

Does the media prefer GMRS or LFMD?

Is GMRS or LFMD more profitable?

Summary

How does LifeMD compare to Fulgent Genetics?

Which has better valuation and earnings, LFMD or FLGT?

Does the media refer more to LFMD or FLGT?

Is LFMD or FLGT more profitable?

Do analysts rate LFMD or FLGT?

Do institutionals and insiders have more ownership in LFMD or FLGT?

Which has more risk & volatility, LFMD or FLGT?

Summary

How does LifeMD compare to Oncology Institute?

Does the media favor LFMD or TOI?

Which has better valuation and earnings, LFMD or TOI?

Is LFMD or TOI more profitable?

Which has more volatility and risk, LFMD or TOI?

Do analysts prefer LFMD or TOI?

Do insiders and institutionals hold more shares of LFMD or TOI?

Summary

How does LifeMD compare to Strata Critical Medical?

Do insiders & institutionals have more ownership in SRTA or LFMD?

Which has higher earnings & valuation, SRTA or LFMD?

Does the media favor SRTA or LFMD?

Is SRTA or LFMD more profitable?

Do analysts recommend SRTA or LFMD?

Which has more volatility and risk, SRTA or LFMD?

Summary

How does LifeMD compare to Cross Country Healthcare?

Does the media favor LFMD or CCRN?

Do insiders and institutionals have more ownership in LFMD or CCRN?

Is LFMD or CCRN more profitable?

Which has more risk & volatility, LFMD or CCRN?

Do analysts recommend LFMD or CCRN?

Which has preferable earnings and valuation, LFMD or CCRN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFMD vs. The Competition

LifeMD Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools